This new drug is entering a Phase I trial at Dana Farber Cancer Center for patients with GIST who have progressed on Gleevec. Trial participants may have tried other drugs besides Gleevec.

This Medscape interview is free-access, but Medscape requires a simple user registration to view its content.

Below is an informal summary of a consensus summary on GIST treatment by an international group of GIST experts. The consensus conference to develop this guideline was sponsored by the European Society of Medical Oncology (ESMO) with a grant from Novartis. A meeting was held in March 2004 among 41 experts from 12 countries from around the world (not just Europe). The resulting paper was published in March 2005 in the Annals of Oncology, volume 16 pages 566-578. The paper is not free-access. This is a paper your oncologist should obtain and read. Its purpose is to continue in the path started by the NCCN guidelines (which it cites) to develop a standard of care for GIST.

As part of an agency-wide initiative to speed development of new medical products through the science of pharmacogenomics, the Food and Drug Administration (FDA) today issued a final guidance titled "Pharmacogenomic Data Submissions."

This EurekAlert neww story indicates a trial of AMN107 is coming soon for GIST. AMN107 is a followup to Gleevec being developed by Novartis.

Swedish researchers developed a method of predicting the probability GIST will recur after surgery.